<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Betamethasone Valerate - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Betamethasone Valerate</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../index.html#/sickbay-meds">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Derm / ENT / Eye / Topicals</div>
      <h1>Betamethasone Valerate</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Betamethasone Valerate 0.1% Cream</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Inflammatory dermatoses (eczema, contact dermatitis, psoriasis, etc.)</strong>
            <ul>
              <li>Apply thin layer of 0.1% cream to affected area(s) 1â€“2 times daily</li>
              <li>Use twice daily initially for acute flares; reduce to once daily as condition improves</li>
              <li>Rub in gently and completely</li>
            </ul>
          </li>
          <li><strong>Duration</strong>
            <ul>
              <li>Use for shortest duration necessary to control symptoms</li>
              <li>Reassess if no improvement after 2 weeks</li>
              <li>Avoid prolonged continuous use (risk of skin atrophy and systemic absorption)</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Corticosteroid-responsive dermatoses including eczema, atopic dermatitis, contact dermatitis</li>
          <li>Psoriasis (limited areas; not as sole therapy for extensive disease)</li>
          <li>Seborrheic dermatitis</li>
          <li>Other inflammatory skin conditions responsive to potent topical corticosteroids</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to betamethasone or other corticosteroids</li>
          <li>Untreated bacterial, viral, or fungal skin infections (including rosacea, acne, perioral dermatitis)</li>
          <li>Do not use on face, groin, or axillae unless specifically directed (higher absorption/atrophy risk)</li>
          <li>Avoid occlusive dressings unless directed (increases absorption and side effect risk)</li>
          <li>Caution in children: use lower potency agents when possible; higher risk of systemic absorption and growth suppression with extensive or prolonged use</li>
          <li>Pregnancy/breastfeeding: use only if clearly needed and on limited areas</li>
          <li>Not for ophthalmic use</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Local: skin atrophy, striae, telangiectasia (with prolonged use)</li>
          <li>Burning, itching, dryness, irritation (especially initially)</li>
          <li>Folliculitis, hypertrichosis, acneiform eruptions</li>
          <li>Hypopigmentation</li>
          <li>Secondary infection (fungal or bacterial)</li>
          <li>Systemic effects (with extensive or prolonged use): HPA axis suppression, Cushing's syndrome, hyperglycemia</li>
          <li>Contact dermatitis (allergic sensitization to corticosteroid or vehicle)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>Wash and dry affected area before application</li>
          <li>Apply thin layer and rub in gently until absorbed</li>
          <li>Wash hands after application (unless hands are the treated area)</li>
          <li>Avoid contact with eyes and mucous membranes</li>
          <li>Do not apply to open wounds or weeping lesions unless specifically directed</li>
          <li>If using on large areas or under occlusion: limit duration and monitor for systemic effects</li>
          <li>For eczema: may use with emollients; apply emollient first, then topical steroid, or as directed</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Clinical response (reduction in erythema, pruritus, scaling)</li>
          <li>Signs of skin atrophy (thinning, shiny appearance, easy bruising) with prolonged use</li>
          <li>Secondary infection (worsening redness, pustules, lack of improvement)</li>
          <li>If no improvement after 2 weeks: reassess diagnosis and treatment plan</li>
          <li>If using extensively or for prolonged periods: monitor for signs of systemic corticosteroid effects (hyperglycemia, HPA suppression)</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Potent topical steroid: effective for inflammatory dermatoses but requires careful use to avoid adverse effects</li>
          <li>Environmental factors (sun exposure, salt water, dry air, friction from clothing/gear) can exacerbate dermatitis; address environmental triggers when possible</li>
          <li>Counsel on proper use: thin layer, limited duration, avoid face/intertriginous areas unless directed</li>
          <li>If skin infection suspected (bacterial/fungal): treat infection before or concurrently with topical steroid, or use combination product if available and appropriate</li>
          <li>Taper frequency as condition improves rather than abrupt discontinuation (helps prevent rebound flare)</li>
          <li>Document area treated, frequency, and duration to track cumulative exposure</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (betamethasone valerate cream - ratio-Ectosone): <a href="https://pdf.hres.ca/dpd_pm/00064283.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00064283.PDF</a></li>
          <li>Health Canada product monograph (betamethasone valerate - Betaderm): <a href="https://pdf.hres.ca/dpd_pm/00047046.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00047046.PDF</a></li>
          <li>National Eczema Association - Topical Corticosteroids: <a href="https://nationaleczema.org/eczema/treatment/topicals/steroids/" target="_blank" rel="noopener">https://nationaleczema.org/eczema/treatment/topicals/steroids/</a></li>
          <li>Medscape - Betamethasone Valerate Topical: <a href="https://reference.medscape.com/drug/betaderm-betamethasone-valerate-topical-343408" target="_blank" rel="noopener">https://reference.medscape.com/drug/betaderm-betamethasone-valerate-topical-343408</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
